Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3 studies found for:    at-101 sclc
Show Display Options
Rank Status Study
1 Completed Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer
Condition: Small Cell Lung Cancer
Interventions: Drug: AT-101;   Drug: topotecan
2 Completed R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: R-(-)-gossypol acetic acid;   Drug: cisplatin;   Drug: etoposide
3 Completed
Has Results
R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer
Interventions: Drug: R-(-)-gossypol acetic acid;   Other: pharmacological study;   Other: laboratory biomarker analysis

Study has passed its completion date and status has not been verified in more than two years.